SLNSW-Ixekizumab, an interleukin-17A specific monoclona...-TN_cdi_proquest_journals_1883334779

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

Full title: Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

Author/creator: SPIRIT-P1 Study Group, Mease, Philip J, van der Heijde, Désirée, Ritchlin, Christopher T, Okada, Masato, Cuchacovich, Raquel S, Shuler, Catherine L, Lin, Chen-Yen, Braun, Daniel K, Lee, Chin H, Gladman, Dafna D.

Call Numbers:

Record Identifier: TN_cdi_proquest_journals_1883334779

Language: English

Formats: Articles

Publishers: England: British Medical Association

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1883334779

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

    Record identifier

    TN_cdi_proquest_journals_1883334779

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1883334779

    Share

    Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1883334779

    Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

    Full title

    Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

    Author / Creator

    SPIRIT-P1 Study Group ; Mease, Philip J ; van der Heijde, Désirée ; Ritchlin, Christopher T ; Okada, Masato ; Cuchacovich, Raquel S ; Shuler, Catherine L ; Lin, Chen-Yen ; Braun, Daniel K ; Lee, Chin H ; Gladman, Dafna D

    Publisher

    England: British Medical Association

    Journal title

    Annals of the rheumatic diseases, 2017, Vol.76 (1), p.79-87

    Record Identifier

    TN_cdi_proquest_journals_1883334779

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    1506 Adalimumab - adverse effects Adalimumab - therapeutic use Adult Analysis Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - administration & dosage Antirheumatic Agents - therapeutic use Arthritis, Psoriatic - drug therapy Care and treatment Clinical and Epidemiological Research DMARDs (biologic) Double-Blind Method Female Humans Interleukin-17 - antagonists & inhibitors Male Middle Aged Psoriatic Arthritis Spondyloarthritis Treatment Treatment Outcome

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_journals_1883334779

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1883334779

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections